» Articles » PMID: 34363901

An Overview of Phase 2 Clinical Trial Designs

Overview
Specialties Oncology
Radiology
Date 2021 Aug 7
PMID 34363901
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Clinical trials are studies to test new treatments in humans. Typically, these treatments are evaluated over several phases to assess their safety and efficacy. Phase 1 trials are designed to evaluate the safety and tolerability of a new treatment, typically with a small number of patients (eg, 20-80), generally spread across several dose levels. Phase 2 trials are designed to determine whether the new treatment has sufficiently promising efficacy to warrant further investigation in a large-scale randomized phase 3 trial, as well as to further assess safety. These studies usually involve a few hundred patients. This article provides an overview of some of the most commonly used phase 2 designs for clinical trials and emphasizes their critical elements and considerations. Key references to some of the most commonly used phase 2 designs are given to allow the reader to explore in more detail the critical aspects when planning a phase 2 trial. A comparison of 3 potential designs in the context of the NRG-HN002 trial is presented to complement the discussion about phase 2 trials.

Citing Articles

Blunted Blood Pressure Dipping During Night Shift Work: Does It Matter? Can We Intervene?.

Patterson P, Hostler D, Muldoon M, Buysse D, Reis S Am J Ind Med. 2025; 68(4):313-320.

PMID: 39953922 PMC: 11898159. DOI: 10.1002/ajim.23711.


Ethical and academic dilemmas in authorship of clinical research publications: a medical oncologist's perspective.

Tanriverdi O Med Oncol. 2025; 42(3):74.

PMID: 39932633 PMC: 11813949. DOI: 10.1007/s12032-025-02617-4.


Leaflet: Operative Steps for Interventional Studies in Neuroscience.

Meringolo M, Delle Monache S, Martella G, Peppe A Neurol Int. 2025; 17(1).

PMID: 39852766 PMC: 11767703. DOI: 10.3390/neurolint17010001.


Study design of herbal medicine clinical trials: a descriptive analysis of published studies investigating the effects of herbal medicinal products on human participants.

Koonrungsesomboon N, Sakuludomkan C, Takuathung M, Klinjan P, Sawong S, Perera P BMC Complement Med Ther. 2024; 24(1):391.

PMID: 39516879 PMC: 11549860. DOI: 10.1186/s12906-024-04697-7.


Efficacy and safety of JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone: a multicenter, phase Ib/II study.

Xu H, Zhou Y, Liang L, Shen J, Yan W, Wang J Nat Commun. 2024; 15(1):9541.

PMID: 39500883 PMC: 11538294. DOI: 10.1038/s41467-024-53686-4.


References
1.
Farlow J, Birkeland A, Swiecicki P, Brenner J, Spector M . Window of opportunity trials in head and neck cancer. J Cancer Metastasis Treat. 2019; 5. PMC: 6638557. DOI: 10.20517/2394-4722.2018.100. View

2.
Thorlund K, Dron L, Park J, Mills E . Synthetic and External Controls in Clinical Trials - A Primer for Researchers. Clin Epidemiol. 2020; 12:457-467. PMC: 7218288. DOI: 10.2147/CLEP.S242097. View

3.
Heller G . Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria. Ann Oncol. 2015; 26(10):2012-6. PMC: 4692987. DOI: 10.1093/annonc/mdv333. View

4.
Simon R . Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10(1):1-10. DOI: 10.1016/0197-2456(89)90015-9. View

5.
Foster J, Freidlin B, Kunos C, Korn E . Single-Arm Phase II Trials of Combination Therapies: A Review of the CTEP Experience 2008-2017. J Natl Cancer Inst. 2019; 112(2):128-135. PMC: 7019095. DOI: 10.1093/jnci/djz193. View